Drugs / Sterofundin ISO
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01515397 | Dec 2011 → Jan 2013 | — | B. Braun Melsungen AG | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT02715466 | Apr 2016 → Dec 2021 | — | B. Braun Melsungen AG | Terminated | No outcome recorded |
| Phase 4 | NCT00936247 | Nov 2009 → Sep 2010 | impaired renal function disease | B. Braun Melsungen AG | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sterofundin ISO | “Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component” NCT00936247 ↗2“Gelofusine balanced combined with Sterofundin ISO” NCT01515397 ↗ “Gelaspan combined with Sterofundin ISO” NCT02715466 ↗ |
| Modality | Other / unclassified | “crystalloid solution” PMID 34078421 ↗ Jun 2021 |